Pharming « Terug naar discussie overzicht

quote:

Teddieke schreef op 6 april 2018 17:06:

Er liggen ook wel blokjes tussen de 1,30 en 1,31 nu.

Fluit maar af! Klaar met de week.

quote:

voda schreef op 6 april 2018 17:07:

[...]
De laatste wanhopige poging van de shorters? :-)

quote:

beeldscherm schreef op 6 april 2018 16:43:

..
Ruconest Account Manager
Pharming Group N.V.
december 2016 – heden (1 jaar 5 maanden)
Highest number of patients shipped 2017
Highest in Volume for Q4 2017
Top 3 in volume 2017
Top 3 in new prescriber 2017

Number 1 in total patients on therapy Q1 2018
Number 1 total volume Q1 2018
Number 1 in total prescribers Q1 2018

quote:

voda schreef op 6 april 2018 17:07:

[...]
De laatste wanhopige poging van de shorters? :-)

quote:

LT belegger schreef op 6 april 2018 16:37:

[...]

OUTLOOK 2018

For the remainder of 2018, the Company expects:

• Continued growth in revenues from sales of RUCONEST®, mainly driven by the USA and Western Europe operations.

• Achievement of positive quarterly net earnings during the year.

• Continued investment in the expansion of production of RUCONEST® in order to ensure continuity of supply to the growing markets in the US, Europe and the Rest of the World.

• Investment in further clinical trial programs for RUCONEST® in acute treatment and prophylaxis of HAE and the development of a small intravenous version and new intramuscular and subcutaneous versions of RUCONEST® as well as research into other routes of administration.

• Investment in clinical trials to explore additional indications for RUCONEST®.

• Investment in development of the new pipeline programs in Pompe disease and Fabry’s disease, and other new development opportunities and assets as these occur.

• Increasing marketing activity where this can be profitable for Pharming.

• We will continue to support all our teams and marketing partners in order to enable the maximization of the sales and distribution potential of RUCONEST® for patients in all territories, as we continue to believe that RUCONEST® represents a fast, effective, reliable and safe therapy option to treat acute angioedema attacks in patients with HAE.

quote:

knaap1 schreef op 6 april 2018 17:14:

we gaan er dag hoog uit.

quote:

B...K schreef op 6 april 2018 17:16:

[...]
Dat zal niet gebeuren.

quote:

zjeeraar schreef op 6 april 2018 17:15:

[...]

Pharming kan gewoon op eigen kracht naar een veel betere koers-waardering.

Gezien de huidige koersadviezen is het nu een echt nog steeds een koopje vind ik.

quote:

B...K schreef op 6 april 2018 17:16:

[...]
Dat zal niet gebeuren.

quote:

beeldscherm schreef op 6 april 2018 16:43:

..
Ruconest Account Manager
Pharming Group N.V.
december 2016 – heden (1 jaar 5 maanden)
Highest number of patients shipped 2017
Highest in Volume for Q4 2017
Top 3 in volume 2017
Top 3 in new prescriber 2017

Number 1 in total patients on therapy Q1 2018
Number 1 total volume Q1 2018
Number 1 in total prescribers Q1 2018

quote:

Eagle-57 schreef op 6 april 2018 16:31:

[...]
Vraag niet hoe het kan, maar geniet ervan... ;-)

( Aan de andere kant, heeft u PH aandelen? Of afgelopen jaar PH gevolgd? Dan is er nu imho een terechte correctie...)